Drug resistance: Overcoming resistance in acute myeloid leukaemia treatment

Nature Reviews Cancer

Volumn 14, Issue 7, 2014, Pages 452-453

  Lokody, Isabel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE 1A1; RIBAVIRIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; VISMODEGIB;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; DRUG MECHANISM; DRUG SENSITIVITY; GLUCURONIDATION; HUMAN; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; LEUKEMIA RELAPSE; MASS SPECTROMETRY; NOTE; PRIORITY JOURNAL; SAMPLE SIZE;

DRUG RESISTANCE, NEOPLASM; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; HEDGEHOG PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; TRANSCRIPTION FACTORS;

EID: 84903155114     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3776     Document Type: Note

References (2)

1. Zahreddine, H. A. et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature http://dx.doi.org/10.1038/ nature13283 (2014
2. Assouline, S. et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114, 257-260 (2009)